Cubist

Buying Into Cubist's Art Against Resistant Bacteria

Buying Into Cubist's Art Against Resistant Bacteria

Forbes

Cubist Increases Revenue 30% to $231 Million in the Second Quarter

Cubist Increases Revenue 30% to $231 Million in the Second Quarter

Yahoo

Cubist Sues Hospira Over Cubicin Bacteria Medicine Patent

Cubist Sues Hospira Over Cubicin Bacteria Medicine Patent

Bloomberg

Cubist Earnings Narrowly Exceed Expectations

Cubist Earnings Narrowly Exceed Expectations

Investors.com

Cubist's antibiotic gets generic threat from Hospira

Cubist's antibiotic gets generic threat from Hospira

Reuters

Cubist Pharmaceuticals extends offer to buy Adolor shares until Friday

Cubist Pharmaceuticals extends offer to buy Adolor shares until Friday

Yahoo/AP

Biotech Takeovers Could Heat Up These Stocks

Biotech Takeovers Could Heat Up These Stocks

Seeking Alpha

Cubist Pharmaceuticals-Adolor waiting period expires

Cubist Pharmaceuticals-Adolor waiting period expires

Bizjournals.com

Cubist’s merger partner Adolor swings to third-quarter profit

Cubist’s merger partner Adolor swings to third-quarter profit

Bizjournals.com

Cubist begins tender offer for Adolor

Cubist begins tender offer for Adolor

Bizjournals.com